Our recent meeting with the Eicher Motors (EIM) management suggests that Royal Enfield (RE) is seeing good traction in its newly-launched Thunderbird X – a fact also corroborated by our channel checks.
Biocon is focused on its biopharma verticals that include APIs and generic formulations (41% of FY17 revenues), biosimilars (~14% of FY17 revenues) and proprietary molecules both commercialized and under development.
We recently met the management of Capital First (CAFL). The proposed merger of IDFC Bank (IDFCB) with CAFL is likely to fructify by mid-FY19, creating a financial services entity with total assets of ~INR1.5t.
We recently met the management of Dilip Buildcon (DBL) to get a perspective of the company’s business and future strategies. We also visited its Lucknow-Sultanpur HA project to gauge the company’s execution capabilities.